Evidence map›Paper›PMID 37370831›Full record

ArticleCancers2023

Nigericin Boosts Anti-Tumor Immune Response via Inducing Pyroptosis in Triple-Negative Breast Cancer.

Lisha Wu, Shoumin Bai, Jing Huang, Guohui Cui, Qingjian Li, Jingshu Wang, Xin Du, Wenkui Fu, Chuping Li, Wei Wei and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Microbiology spectrum · 2025
    Article
  12. Nigericin Induces Paraptosis-Like Cell Death Instead of Pyroptosis in Corneal Keratocytes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Nanomaterials Enhance Pyroptosis-Based Tumor Immunotherapy.International journal of nanomedicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Lisha WuDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Shoumin BaiDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Jing HuangDepartment of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Guohui CuiSouth China National Bio-Safety Laboratory, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510600, China.
Qingjian LiDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Jingshu WangDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Xin DuDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Wenkui FuDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Chuping LiDepartment of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Wei WeiDepartment of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Huan LinDepartment of Breast Oncology, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
Man-Li LuoGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.ORCID 0000-0002-6435-7303
Sun Yat-sen University · CNPeking University Shenzhen Hospital · CNGuangzhou University of Chinese Medicine · CN

Funding

Beijing Xisike Clinical Oncology Research Foundation YHR2020QN-0686Guangdong Science and Technology Department 2020B1212060018, 2020B1212030004National Natural Science Foundation of China 82073048Natural Science Foundation of Guangdong Province 2020A1515110756, 2023A1515010916
6 · The paper itself

Abstract

Although immune checkpoint inhibitors improved the clinical outcomes of advanced triple negative breast cancer (TBNC) patients, the response rate remains relatively low. Nigericin is an antibiotic derived from

Indexed as

anti-tumor immune-responseimmune checkpoint inhibitornigericinpyroptosistriple-negative breast cancer

Identifiers

PMID37370831
PMCPMC10296105
OpenAlexW4380988942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.